board of directors


Nikolay savchuk (managing partner, torrey pines investment)

1994, Master of Science, Department of Applied Physics and Mathematics, Moscow Institute of Physics and Technology, Moscow, Russia.
2000, PhD, Department of Applied Physics and Mathematics, Moscow Institute of Physics and Technology, Moscow, Russia.
Dr. Savchuk is the author of over 100 scientific publications. He frequently presented at numerous international conferences, including the American Chemical Society Meetings, Society of Biomolecular Screening, World Vaccine Congress, Open Innovations Summit, BIO International Convention, Pharmaceutical Strategic Alliances and other industrial, scientific and trading events.

Dr. Savchuk is the CEO of ChemDiv, Inc. (San Diego, CA) and Managing Partner at Torrey Pines Investment (San Diego, CA), Member of the Board of Directors at ChemRar High Tech Center (Moscow, Russia) and Chairman of the Board of Directors of its companies: Chemical Diversity Research Institute, Viriom, NewVac, TeaRx, and SatRx.

Dr. Savchuk is a member of U.S.-Russian Bilateral Presidential Commission's Working Group on Public Health, a member of the expert council of the Strategic Initiatives Agency of the Russian government; Member of the Board of the "Northern" BioPharm Cluster at Moscow Institute of Physics and Technology (MIPT); Co-founder and member of the Advisory Board of an innovative regional cluster "PhysTech 21"; Director for Strategic Development of Moscow Institute of Physics and Technology (MIPT).

Dr. Savchuk was a co-founder of the Inel Group of IT and media companies in Singapore and Russia, and is managing a number of its companies. 
Dr. Savchuk's main interest is life sciences including rational drug design, drug discovery and digital health technologies. Dr. Savchuk led and continues to manage successful investments in pharmaceutical and drug development companies. 


jennifer giottonini Cayer (Board member, travus therapeutics)


Dr. Cayer received her BS in Bioengineering from University of California, San Diego.


Ms. Giottonini Cayer serves on the board of Travus Therapeutics, Chromis Therapeutics, and Athena San Diego. She most recently held the COO position at Rempex Pharmaceuticals before selling the company to The Medicines Company. Jennifer Cayer has over 25 years of biotech, pharmaceutical and medical device experience. She has executed multiple alliances with pharmaceutical and biotech companies, worth over $1B, including company acquisitions, drug licensing, technology licensing, drug discovery and development collaborations, and the creation of spinout businesses. Prior to Rempex Pharmaceuticals, she was with Conatus Pharmaceuticals, a company she co-founded and where she served as the Senior Vice President or Corporate Development. Prior to Conatus, she was the head of Corporate Development for Idun Pharmaceuticals, Inc. Ms. Cayer spent five years at Isis Pharmaceuticals where she served as Vice President, Business Development. She has held various technical, marketing, and operational roles at Gensia and Puritan Bennett (Tyco). She co-founded and co-chairs the Advisory Committee for Biocom's Global Partnering Conference. 


ronald demuth (venture partner, torrey pines investment)

Mr. Demuth is the President and Venture Partner of Torrey Pines Investment, responsible for the company's strategic investments. Prior to Torrey Pines Investment, he worked as a General Manager of Integrated Genomics, leading its M&A strategy, and in several roles at the University of Chicago, including administrating an Arch Venture corporation. Mr. Demuth has 30 years of research and management experience in the international life science industry and academia.